Aerie Pharmaceuticals’ (AERI) “Buy” Rating Reaffirmed at Mizuho
“We continue to believe that 2018 Rhopressa sales can land in the upper range of management guidance and recent performance reinforces our view.”,” Mizuho’s analyst wrote.
Several other analysts have also commented on the stock. BidaskClub upgraded shares of Aerie Pharmaceuticals from a strong sell rating to a sell rating in a research report on Monday, October 15th. Zacks Investment Research upgraded shares of Aerie Pharmaceuticals from a sell rating to a buy rating and set a $60.00 target price on the stock in a research report on Wednesday, October 10th. JMP Securities set a $80.00 target price on shares of Aerie Pharmaceuticals and gave the company a buy rating in a research report on Wednesday, October 10th. ValuEngine lowered shares of Aerie Pharmaceuticals from a strong-buy rating to a buy rating in a research report on Saturday, October 6th. Finally, Cantor Fitzgerald reiterated a buy rating and issued a $86.00 target price on shares of Aerie Pharmaceuticals in a research report on Tuesday, October 2nd. One investment analyst has rated the stock with a sell rating and eleven have issued a buy rating to the company. Aerie Pharmaceuticals has a consensus rating of Buy and a consensus price target of $82.30.
Aerie Pharmaceuticals (NASDAQ:AERI) last released its quarterly earnings results on Tuesday, November 6th. The company reported ($1.73) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.33) by ($0.40). The company had revenue of $7.30 million for the quarter, compared to the consensus estimate of $5.63 million. Research analysts predict that Aerie Pharmaceuticals will post -4.51 earnings per share for the current fiscal year.
In other news, COO Thomas A. Mitro sold 190,000 shares of Aerie Pharmaceuticals stock in a transaction dated Monday, August 27th. The shares were sold at an average price of $60.27, for a total value of $11,451,300.00. Following the sale, the chief operating officer now owns 234,147 shares in the company, valued at $14,112,039.69. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Casey C. Kopczynski sold 11,000 shares of Aerie Pharmaceuticals stock in a transaction dated Tuesday, September 4th. The shares were sold at an average price of $60.09, for a total transaction of $660,990.00. Following the completion of the sale, the insider now owns 148,517 shares in the company, valued at approximately $8,924,386.53. The disclosure for this sale can be found here. In the last quarter, insiders sold 324,117 shares of company stock worth $19,459,226. Company insiders own 10.53% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in AERI. Frontier Capital Management Co. LLC purchased a new position in shares of Aerie Pharmaceuticals in the second quarter worth about $24,685,000. BlackRock Inc. lifted its stake in shares of Aerie Pharmaceuticals by 9.0% in the second quarter. BlackRock Inc. now owns 2,991,101 shares of the company’s stock worth $202,049,000 after buying an additional 246,686 shares in the last quarter. PointState Capital LP lifted its stake in shares of Aerie Pharmaceuticals by 524.7% in the second quarter. PointState Capital LP now owns 281,600 shares of the company’s stock worth $19,022,000 after buying an additional 236,524 shares in the last quarter. FMR LLC lifted its stake in shares of Aerie Pharmaceuticals by 25.4% in the second quarter. FMR LLC now owns 1,095,652 shares of the company’s stock worth $74,011,000 after buying an additional 221,582 shares in the last quarter. Finally, Candriam Luxembourg S.C.A. lifted its stake in shares of Aerie Pharmaceuticals by 168.5% in the third quarter. Candriam Luxembourg S.C.A. now owns 326,800 shares of the company’s stock worth $20,115,000 after buying an additional 205,100 shares in the last quarter. Institutional investors and hedge funds own 96.43% of the company’s stock.
Aerie Pharmaceuticals Company Profile
Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.
Featured Story: Price to Earnings Ratio (PE)
Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.